Project Grant K99CA318239
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $149K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Cancer Institute awarded The Leland Stanford Junior University $158,499 on May 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research investigating the role of CDKN2A in lung adenocarcinoma metastasis. The award funds exploration of how CDKN2A inactivation promotes metastatic colonization and growth in oncogenic KRAS-driven lung adenocarcinoma. The research employs CRISPR-CAS9 somatic genome editing and tumor barcoding in genetically engineered mice...
- The National Cancer Institute awarded The Leland Stanford Junior University $635,340 on May 4, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct functional genomic dissection of lung cancer in vivo. Stanford will integrate genetically engineered mouse models, multiplexed CRISPR-based genome editing, and tumor barcoding to assess tumor suppressor gene function across multiple genotypes and their effects on lung tumor initiation and growth in parallel. In Aim 1,...
- The National Cancer Institute awarded The Leland Stanford Junior University $143,278 under the Cancer Research Manpower program (CFDA 93.398) on January 1, 2026, to support research investigating evolutionary antagonism between tumors and lymphocytes. The recipient will conduct analyses of clonal diversity in metastatic cancer cells using viral integration site mapping across nine rounds of in vivo selection, perform single-cell transcriptomics to profile phenotypic diversity in relation to...
- The National Cancer Institute awarded The Leland Stanford Junior University $137,266 on July 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop comprehensive profiling methods for T-cell lymphomas and personalized therapeutic interventions. The project encompasses three research aims. Aim 1 develops disease monitoring and clonal evolution assessment in T-cell lymphoma by integrating targeted sequencing of cell-free DNA to detect circulating tumor DNA, viral genomes,...
- The National Cancer Institute awarded The Leland Stanford Junior University $100,228 on February 13, 2027, under the Cancer Research Manpower program (CFDA 93.398) to support biomedical training and research in cancer immunotherapy. Performance extends through September 21, 2029, at Stanford's Palo Alto, California location. The award funds research on co-engineered CAR T cells and CAR macrophages for glioblastoma treatment. The project applies a synthetic cytokine receptor (SCR) platform to...
- The National Cancer Institute awarded the University of California, Los Angeles $540,204 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop small molecule modulators targeting the RNA exonuclease polynucleotide phosphorylase (PNPASE) as a therapeutic strategy for therapy-resistant, immune-cold KRAS/LKB1 mutant non-small cell lung cancer. The award funds research into PNPASE inhibitors (MTPNPIs) that induce accumulation of cytosolic mitochondrial...
- The National Cancer Institute, within the Department of Health and Human Services, awarded The Leland Stanford Junior University $606,756 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award funds development and validation of foundation model-augmented artificial intelligence tools to enable accurate and efficient image guidance in upright proton therapy for lung cancer treatment. The research will create a vision-language framework for...
- The National Cancer Institute awarded The Leland Stanford Junior University $357,370 on May 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on reprogramming inflammatory fibroblasts to overcome therapeutic resistance in pancreatic adenocarcinoma. The research investigates cancer-associated fibroblasts (CAFs) and their role in pancreatic ductal adenocarcinoma (PDAC) fibrosis and therapeutic resistance. Stanford's preliminary work has demonstrated that...
- The National Cancer Institute awarded The Leland Stanford Junior University $166,968 on August 15, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop single-molecule multi-omics sequencing methods for spatially resolved epigenetic profiling of extrachromosomal DNA (ecDNA) molecules and to investigate the relationship between ecDNA spatial organization, epigenetic landscape, and transcriptional regulation. The work addresses a technical gap in understanding ecDNA's...
- The National Cancer Institute awarded The Leland Stanford Junior University $626,743 on July 7, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop intraoperative molecular imaging of lung cancer using panitumumab-IRDYE800 (PAN800). The funded research addresses accurate tumor localization during lung cancer surgery, particularly for small, less dense, or deep tumors and minimally invasive surgical approaches where palpation is difficult. Current techniques...